**AGREEMENT BETWEEN INSTITUT PASTEUR**

 **AND RECIPIENT OF THE STRAIN Vim1/Vim1**

1 – The mouse strain Vim1/Vim1, which contains a null mutation in the vimentin gene, has been described and published in Colucci-Guyon E, Portier MM, Dunia I, Paulin D, Pournin S, Babinet C. Mice lacking vimentin develop and reproduce without an obvious phenotype. Cell. 1994 Nov 18;79(4):679-94. publication) . The strain Vim1/Vim1, its derivatives and progenies are called herein after "the IP biological material" will be made available to the Recipient subject to the following terms:

2 - The IP biological material will be used by the Recipient's Laboratory only for application in basic research program as mentioned in his letter dated……………….

The IP biological material will not be used for any commercial purposes whatsoever by the Recipient's Laboratory or his Institution.

No other right or license is granted or implied hereby.

The IP biological material will not be distributed to any other party, scientist, laboratory either within the Recipient's Institution or external to his Institution and in particular to companies without the prior written authorization of the Director of Institut Pasteur.

3 - The research investigator agrees to communicate to Dr Emma Colucci-Guyon (Institut Pasteur), prior publication, the results obtained with the IP biological material.

4 - In all publications relative to the use of this IP biological material by Recipient, the name of the IP biological material will be employed and reference to Dr Emma Colucci-Guyon et al's work will be made by the Recipient.

5 - The IP biological material is provided as a service to the research community. The Recipient and his Institution agree to waive all claims against Institut Pasteur from all damages arising from his use, storage and handling of this IP biological material by the Recipient. The Recipient and his Research Institution will take all formalities relative to the importation of the biological material.

6 - The IP biological material is supplied to the Recipient with no warranties, express or implied. The Institut Pasteur makes no representation that the use of "The IP biological material" will no infringe any patent or proprietary rights of third parties.

7 - The Recipient and Research Institution agree that IP biological material will not be used in human subjects, in clinical trials, or for diagnostic purposes involving human subjects.

8 - This Agreement is governed by the laws of France.

If the foregoing terms are acceptable, please sign in the space below, have a representative of the Recipient's Institution sign in the space indicated for the signature, and return two (2) originals of the present agreement for the attention of Dr Emma Colucci-Guyon (Unité de Macrophages et Developpement de l’Immunité,  Institut Pasteur, 25 rue du Docteur-Roux - 75015 PARIS), and the one (1) original for the attention of the "Service des Brevets et Inventions" (Institut Pasteur).

The undersigned research Investigator ("Recipient") and Institution agree and accept the foregoing.

|  |  |  |  |
| --- | --- | --- | --- |
| **Name of Research** | **Research Institution** | **Institut Pasteur's** | **Agreed by** |
| **Investigator** |  | **Scientist** |  |
| (Recipient of the IP biological material ) | Legal Representative Officer | Emma Colucci-Guyon | Alain GUEDON |
|  |  | PhD, Permanent Scientific staff of the Pasteur Institut | Executive Vice President Business Development |
|  |  | Institut Pasteur | Institut Pasteur |
|  | Represented by : |  |  |
|  |  |  |  |
| Date : | Date : | Date : | Date : |
| Signature : | Signature : | Signature : | Signature : |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |